Gripil Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 25-07-2024
- Paid Up Capital ₹ 1.20 M
as on 25-07-2024
- Company Age 15 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 21.85 Cr
as on 25-07-2024
- Revenue 49.24%
(FY 2023)
- Profit 65.66%
(FY 2023)
- Ebitda 24.75%
(FY 2023)
- Net Worth 5.29%
(FY 2023)
- Total Assets 17.05%
(FY 2023)
About Gripil Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 1.20 M.
The company currently has active open charges totaling ₹21.85 Cr.
Chandan Soni and Aarti Soni serve as directors at the Company.
- CIN/LLPIN
U24100MH2009PTC194336
- Company No.
194336
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Jul 2009
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Virar, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Gripil Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chandan Soni  | Director | 23-Jul-2009 | Current |
| Aarti Soni | Director | 23-Jul-2009 | Current |
Financial Performance and Corporate Structure Insights of Gripil Pharmaceuticals.
Gripil Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 49.24% increase. The company also saw a substantial improvement in profitability, with a 65.66% increase in profit. The company's net worth moved up by a moderate rise of 5.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gripil Pharmaceuticals?
In 2023, Gripil Pharmaceuticals had a promoter holding of 100.00%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 26 Mar 2024 | ₹20.00 Cr | Open |
Hdfc Bank Limited Creation Date: 01 Mar 2023 | ₹7.50 M | Open |
The Saraswat Co-Op Bank Ltd Creation Date: 21 Oct 2015 | ₹1.00 M | Open |
How Many Employees Work at Gripil Pharmaceuticals?
Gripil Pharmaceuticals has a workforce of 11 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gripil Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gripil Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
